Medicinsk godkendt artikel
Atogepant is used as a preventive treatment for migraine.
Aquipta has been developed specifically to prevent migraines and is approved for adults who have at least 4 seizure days per month.
It is known that CGRP (calcitonin gene-related peptide), which is formed in our nervous system, plays an active role in a migraine attack.
Atogepan, which is the active substance in Aquipta is thought to work by blocking the activity of the CGRP molecule in the brain. This can decrease the number and strength of your migraine attacks.
Aquipta has a half-life of about 11 hours, meaning that from the time you stop taking aquipta, it is out of the body within a few days.
About 1-10% experience nausea, constipation, fatigue, decreased appetite and weight loss.
If you experience side effects that are not mentioned here, we would like to be notified so that we can report them to the Danish Medicines Agency.
Aquipta must not be used by pregnant women and breast-feeding mothers.
You must stop taking Aquipta for at least 5 days before trying to get pregnant.
Aquipta should not be used if you have severe hepatic impairment.
With impaired renal function, the dose of Aquipta is reduced to 10 mg
Before starting treatment with Aquipta you must have a control blood test for liver and kidney numbers
You should take 1 tablet of 60 mg once a day. However, if you have impaired renal function, you should only take 1 tablet of 10 mg once a day.
Aquipta can be consumed morning or evening. The tablets can be swallowed whole, chewed or crushed and can be consumed with or without food.
If you forget to take a dose, take it as soon as possible. If you miss a dose for a whole day, skip it and take the next dose as planned.
